Rockwell Medical, Inc. (RMTI) Financial Statements (2024 and earlier)

Company Profile

Business Address 30142 WIXOM ROAD
WIXOM, MI 48393
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:14,90016,80021,50027,60030,7809,914
Cash and cash equivalents8,95910,89410,10212,98030,7809,914
Short-term investments5,9065,94011,39014,584  
Other undisclosed cash, cash equivalents, and short-term investments35(34)836  
Receivables5,4116,0216,2597,3678,0907,121
Inventory, net of allowances, customer advances and progress billings5,8145,5955,8145,0205,1715,531
Inventory5,8145,5955,8145,0205,1715,531
Other undisclosed current assets1,4401,2741,7372,3713,2042,231
Total current assets:27,56529,69035,31042,35847,24524,797
Noncurrent Assets
Inventory, Noncurrent1,2761,2761,2761,1931,4811,523
Finance lease, right-of-use asset, after accumulated amortization2,1852,326    
Operating lease, right-of-use asset3,4703,558    
Property, plant and equipment2,0932,1792,1942,2642,2892,377
Intangible assets, net (including goodwill)921921921921921921
Goodwill921921921921921921
Intangible assets, net (excluding goodwill)      
Other noncurrent assets527522523522509618
Other undisclosed noncurrent assets   6,4116,9286,6717,200
Total noncurrent assets:10,47210,78211,32511,82811,87112,639
TOTAL ASSETS:38,03740,47246,63554,18659,11637,436
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,6909,56111,75511,94410,0418,597
Employee-related liabilities3,0062,439
Accounts payable5,9275,2024,0533,0512,9424,224
Accrued liabilities3,7634,3597,7025,8874,6604,373
Deferred revenue2592591,7312,1642,1692,163
Debt5,1723,6631,6315,1315,1316,631
Business combination, contingent consideration, liability      
Other undisclosed current liabilities2,3311,5872,574991,1942,204
Total current liabilities:17,45215,07017,69119,33818,53519,595
Noncurrent Liabilities
Long-term debt and lease obligation6,5518,0977,5558,96210,37011,778
Long-term debt, excluding current maturities4,7406,1477,5558,96210,37011,778
Finance lease, liability1,8111,950    
Liabilities, other than long-term debt4,5064,7632,6144,5795,1195,470
Deferred revenue2,4702,5352,6004,5655,1055,456
Other liabilities141414141414
Operating lease, liability2,0222,214    
Business combination, contingent consideration, liability      
Other undisclosed noncurrent liabilities   4,6695,1714,9475,400
Total noncurrent liabilities:11,05712,86014,83818,71220,43622,648
Total liabilities:28,50927,93032,52938,05038,97142,243
Equity
Equity, attributable to parent, including:9,52812,54214,10616,13620,145(4,807)
Additional paid in capital403,203402,894402,701402,480402,304372,383
Accumulated other comprehensive income137156163544951
Accumulated deficit(393,814)(390,509)(388,759)(386,399)(382,209)(377,242)
Other undisclosed equity, attributable to parent211111
Total equity:9,52812,54214,10616,13620,145(4,807)
TOTAL LIABILITIES AND EQUITY:38,03740,47246,63554,18659,11637,436

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues18,08019,66819,31318,69118,68216,124
Cost of revenue
(Cost of Goods and Services Sold)
(17,047)(17,069)(16,973)(17,914)(16,937)(16,910)
Gross profit:1,0332,5992,3407771,745(786)
Operating expenses(3,992)(4,026)(4,306)(4,485)(6,227)(5,840)
Operating loss:(2,959)(1,427)(1,966)(3,708)(4,482)(6,626)
Nonoperating expense
(Other Nonoperating expense)
(346)(323)(396)(482)(485)(536)
Interest and debt expense(395)(387)(439)(476)(485)(540)
Loss from continuing operations:(3,700)(2,137)(2,801)(4,666)(5,452)(7,702)
Loss before gain (loss) on sale of properties:(4,666)(5,452)(7,702)
Net loss:(3,700)(2,137)(2,801)(4,666)(5,452)(7,702)
Other undisclosed net income attributable to parent395387439476485540
Net loss available to common stockholders, diluted:(3,305)(1,750)(2,362)(4,190)(4,967)(7,162)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(3,700)(2,137)(2,801)(4,666)(5,452)(7,702)
Comprehensive loss:(3,700)(2,137)(2,801)(4,666)(5,452)(7,702)
Other undisclosed comprehensive income, net of tax, attributable to parent376380548481483539
Comprehensive loss, net of tax, attributable to parent:(3,324)(1,757)(2,253)(4,185)(4,969)(7,163)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: